NVAX:NASDAQ
Novavax Inc
$10.11
arrow_upward
+1.10%(+0.11) 1D
$10.13
arrow_upward
+0.20% (+0.020)bedtimeAfter hours
Closed: Sep 18, 4:00:00 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
$9.89
High
$10.14
Low
$9.76
Mkt. cap
1.67B
Avg. vol.
5.13M
Volume
11.15M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
Open
$9.89
High
$10.14
Low
$9.76
Mkt. cap
1.67B
Avg. vol.
5.13M
Volume
11.15M
52-wk high
$11.97
52-wk low
$6.20
EPS
-$1.52
Beta
2.45
Shares outstanding
164.95M
No. of employees
749
News stories
From web sources and news partners
Yahoo Finance
·
4 hours ago
Novavax (NVAX) Beats Stock Market Upswing: What Investors Need to Know
Zacks
·
18 hours ago
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
Yahoo Finance
·
18 hours ago
Novavax (NVAX) Soars 7.0%: Is Further Upside Left in the Stock?
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees749
Founded1987
HeadquartersGaithersburg, Maryland, United States
SectorBiotechnology
Websitenovavax.com